reviewTop 1% cited
Maintenance Immunosuppression with Target-of-Rapamycin Inhibitors is Associated with a Reduced Incidence of De Novo Malignancies
Transplantation · 2005 · Vol. 80(7) · pp. 883–889
H. Myron Kauffman✉(The Fourth People's Hospital)Wida S. CherikhYulin ChengDouglas W. Hanto(Beth Israel Deaconess Medical Center)Barry D. Kahan(Texas Medical Center)
Abstract
Maintenance immunosuppression with the TOR inhibitor drugs, sirolimus and everolimus, is associated with a significantly reduced risk of developing any posttransplant de novo malignancy and non-skin solid malignancy.
Cholangiocarcinoma and Gallbladder Cancer StudiesPneumocystis jirovecii pneumonia detection and treatmentCancer Immunotherapy and BiomarkersImmunosuppressionIncidence (geometry)MedicineSirolimusCancer researchOncologyImmunologyInternal medicine
MeSH terms
EverolimusHumansImmunosuppression TherapyImmunosuppressive AgentsNeoplasmsProtein KinasesIncidenceKidney TransplantationRisk AssessmentSirolimusTOR Serine-Threonine Kinases
Citations
614
FWCI
35.22
field-weighted impact
References
20
Percentile
100%
vs. same field & year
Citations per year
Cited by
Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial
Transplantation · 2009 · 574 citations
Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients
Drugs · 2007 · 393 citations
References
Cancer after Kidney Transplantation in the United States
American Journal of Transplantation · 2004 · 1,049 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.